Deferasirox Patent Expiration
Deferasirox is used for treating allergies and allergic reactions. It was first introduced by Novartis Pharmaceuticals Corp
Deferasirox Patents
Given below is the list of patents protecting Deferasirox, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jadenu | US9283209 | Oral formulations of deferasirox | Nov 21, 2034 | Novartis Pharms Corp |
| Exjade | US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr 05, 2019
(Expired) | Novartis |
| Jadenu | US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr 05, 2019
(Expired) | Novartis Pharms Corp |
| Jadenu Sprinkle | US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr 05, 2019
(Expired) | Novartis |
| Exjade | US6596750 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Jun 24, 2017
(Expired) | Novartis |
| Jadenu | US6596750 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Jun 24, 2017
(Expired) | Novartis Pharms Corp |
Deferasirox's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List